DYAI Strangle Strategy
DYAI (Dyadic International, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
DYAI (Dyadic International, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $25.9M, a beta of 1.17 versus the broader market, a 52-week range of 0.65-1.35, average daily share volume of 79K, a public-listing history dating back to 2008, approximately 6 full-time employees. These structural characteristics shape how DYAI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.17 places DYAI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on DYAI?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current DYAI snapshot
As of May 15, 2026, spot at $0.73, ATM IV 24.60%, IV rank 1.90%, expected move 7.05%. The strangle on DYAI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on DYAI specifically: DYAI IV at 24.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a DYAI strangle, with a market-implied 1-standard-deviation move of approximately 7.05% (roughly $0.05 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DYAI expiries trade a higher absolute premium for lower per-day decay. Position sizing on DYAI should anchor to the underlying notional of $0.73 per share and to the trader's directional view on DYAI stock.
DYAI strangle setup
The DYAI strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DYAI near $0.73, the first option leg uses a $0.77 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DYAI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DYAI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.77 | N/A |
| Buy 1 | Put | $0.69 | N/A |
DYAI strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
DYAI strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on DYAI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on DYAI
Strangles on DYAI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DYAI chain.
DYAI thesis for this strangle
The market-implied 1-standard-deviation range for DYAI extends from approximately $0.68 on the downside to $0.78 on the upside. A DYAI long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current DYAI IV rank near 1.90% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DYAI at 24.60%. As a Healthcare name, DYAI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DYAI-specific events.
DYAI strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DYAI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DYAI alongside the broader basket even when DYAI-specific fundamentals are unchanged. Always rebuild the position from current DYAI chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on DYAI?
- A strangle on DYAI is the strangle strategy applied to DYAI (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With DYAI stock trading near $0.73, the strikes shown on this page are snapped to the nearest listed DYAI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DYAI strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the DYAI strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 24.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DYAI strangle?
- The breakeven for the DYAI strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DYAI market-implied 1-standard-deviation expected move is approximately 7.05%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on DYAI?
- Strangles on DYAI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DYAI chain.
- How does current DYAI implied volatility affect this strangle?
- DYAI ATM IV is at 24.60% with IV rank near 1.90%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.